IL247332B - Adeno-associated virus vector - Google Patents

Adeno-associated virus vector

Info

Publication number
IL247332B
IL247332B IL247332A IL24733216A IL247332B IL 247332 B IL247332 B IL 247332B IL 247332 A IL247332 A IL 247332A IL 24733216 A IL24733216 A IL 24733216A IL 247332 B IL247332 B IL 247332B
Authority
IL
Israel
Prior art keywords
adeno
associated virus
virus vector
vector
virus
Prior art date
Application number
IL247332A
Other languages
Hebrew (he)
Other versions
IL247332A0 (en
Inventor
Michael Linden Ralph
Original Assignee
King S College London
Icahn School Med Mount Sinai
Michael Linden Ralph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50490674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL247332(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by King S College London, Icahn School Med Mount Sinai, Michael Linden Ralph filed Critical King S College London
Publication of IL247332A0 publication Critical patent/IL247332A0/en
Publication of IL247332B publication Critical patent/IL247332B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL247332A 2014-02-17 2016-08-17 Adeno-associated virus vector IL247332B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461940639P 2014-02-17 2014-02-17
GBGB1403684.2A GB201403684D0 (en) 2014-03-03 2014-03-03 Vector
PCT/EP2015/053335 WO2015121501A1 (en) 2014-02-17 2015-02-17 Adeno-associated virus vector

Publications (2)

Publication Number Publication Date
IL247332A0 IL247332A0 (en) 2016-09-29
IL247332B true IL247332B (en) 2021-07-29

Family

ID=50490674

Family Applications (2)

Application Number Title Priority Date Filing Date
IL247332A IL247332B (en) 2014-02-17 2016-08-17 Adeno-associated virus vector
IL279154A IL279154B (en) 2014-02-17 2020-12-02 Adeno-associated virus vector

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL279154A IL279154B (en) 2014-02-17 2020-12-02 Adeno-associated virus vector

Country Status (20)

Country Link
US (4) US20180135076A1 (en)
EP (2) EP3597760A3 (en)
JP (4) JP6602788B2 (en)
KR (1) KR102082032B1 (en)
CN (1) CN106062200B (en)
AU (3) AU2015216847B2 (en)
BR (1) BR112016018598A2 (en)
CA (2) CA3126061C (en)
DK (1) DK3108000T3 (en)
ES (1) ES2749235T3 (en)
GB (1) GB201403684D0 (en)
HU (1) HUE045801T2 (en)
IL (2) IL247332B (en)
MX (1) MX372992B (en)
PL (1) PL3108000T3 (en)
PT (1) PT3108000T (en)
RU (1) RU2743382C2 (en)
SG (1) SG11201606365TA (en)
SI (1) SI3108000T1 (en)
WO (1) WO2015121501A1 (en)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
CA2833905C (en) 2010-04-23 2019-09-10 University Of Massachusetts Multicistronic expression constructs
EP3567106A1 (en) 2010-04-23 2019-11-13 University of Massachusetts Cns targeting aav vectors and methods of use thereof
EP2986635B1 (en) 2013-04-18 2018-10-03 Fondazione Telethon Effective delivery of large genes by dual aav vectors
CN105247044B (en) 2013-05-31 2021-05-07 加利福尼亚大学董事会 Adeno-associated virus variants and methods of use thereof
AU2014324717B2 (en) 2013-09-26 2020-10-08 University Of Florida Research Foundation, Inc. Synthetic combinatorial AAV capsid library for targeted gene therapy
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
US10072251B2 (en) 2014-02-19 2018-09-11 University Of Massachusetts Recombinant AAVS having useful transcytosis properties
CA3276269A1 (en) 2014-03-18 2026-03-02 University Of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
US10975391B2 (en) 2014-04-25 2021-04-13 University Of Massachusetts Recombinant AAV vectors useful for reducing immunity against transgene products
EP3137497B2 (en) * 2014-05-02 2025-03-05 Genzyme Corporation Aav vectors for retinal and cns gene therapy
WO2015187825A2 (en) 2014-06-03 2015-12-10 University Of Massachusetts Compositions and methods for modulating dysferlin expression
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3200830B1 (en) 2014-10-03 2020-09-09 University of Massachusetts High efficiency library-identified aav vectors
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
RU2020140209A (en) 2014-10-21 2021-01-25 Юниверсити Оф Массачусетс RECOMBINANT AAV OPTIONS AND THEIR APPLICATIONS
CN107106689A (en) 2014-11-05 2017-08-29 沃雅戈治疗公司 AADC polynucleotides for treating Parkinson's disease
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Preparations and methods for the treatment of amyotrophic lateral sclerosis
CN112410338A (en) 2014-11-14 2021-02-26 沃雅戈治疗公司 Regulatory polynucleotides
EP3224362B1 (en) * 2014-11-26 2024-09-25 The Regents of The University of California Therapeutic compositions comprising transcription factors and methods of making and using the same
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
WO2016131009A1 (en) 2015-02-13 2016-08-18 University Of Massachusetts Compositions and methods for transient delivery of nucleases
US11046955B2 (en) 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
IL314171A (en) * 2015-09-28 2024-09-01 Univ Florida Methods and compositions for stealth virus antibody vectors
EP3364996B1 (en) 2015-10-22 2021-08-25 University of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
WO2017070525A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Methods and compositions for treating metabolic imbalance in neurodegenerative disease
US12188037B2 (en) 2015-10-22 2025-01-07 University Of Florida Research Foundation, Incorporated Synthetic combinatorial AAV3 capsid library
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
EP3368054A4 (en) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. REGULATORY EXPRESSION USING AN ADENO-ASSOCIATED VIRUS (AAV)
PE20231949A1 (en) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTS OF FACTOR VIII REDUCED WITH CpG, COMPOSITIONS AND METHODS AND USES FOR THE TREATMENT OF HEMOSTASY DISORDERS
PE20181156A1 (en) 2015-11-05 2018-07-19 Bamboo Therapeutics Inc MODIFIED FRIEDREICH ATAXIA GENES AND VECTORS FOR GENE THERAPY
WO2017096162A1 (en) 2015-12-02 2017-06-08 Voyager Therapeutics, Inc. Assays for the detection of aav neutralizing antibodies
EP3875593A1 (en) * 2015-12-11 2021-09-08 California Institute of Technology Targeting peptides for directing adeno-associated viruses (aavs)
AU2016370630B2 (en) * 2015-12-14 2023-04-13 The Trustees Of The University Of Pennsylvania Adeno-associated viral vectors useful in treatment of spinal muscular atropy
WO2017136536A1 (en) 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
WO2017139643A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
WO2017147477A1 (en) * 2016-02-26 2017-08-31 University Of Florida Research Foundation, Inc. Aav heparin mutants that display significantly improved eye and brain transduction
WO2017176929A1 (en) 2016-04-05 2017-10-12 University Of Massachusetts Compositions and methods for selective inhibition of grainyhead-like protein expression
CN107287238B (en) * 2016-04-11 2020-10-16 厦门继景生物技术有限责任公司 Gene vector and gene therapy medicine for treating Leber congenital amaurosis 2 type disease
WO2017181105A1 (en) 2016-04-15 2017-10-19 University Of Massachusetts Methods and compositions for treating metabolic imbalance
WO2017180936A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
KR20220108216A (en) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. Compositions and methods of treating huntington's disease
MA44546B1 (en) * 2016-06-15 2021-03-31 Univ California Variant adeno-associated viruses and methods of use
US11882815B2 (en) 2016-06-15 2024-01-30 University Of Massachusetts Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
CA2971303C (en) 2016-06-21 2026-03-03 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
US11564997B2 (en) 2016-06-29 2023-01-31 Crispr Therapeutics Ag Materials and methods for treatment of friedreich ataxia and other related disorders
US11174469B2 (en) 2016-06-29 2021-11-16 Crispr Therapeutics Ag Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
WO2018002812A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
US11459587B2 (en) 2016-07-06 2022-10-04 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
CA3029132A1 (en) 2016-07-06 2018-01-11 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
EP3485005A1 (en) 2016-07-12 2019-05-22 The University Of Manchester Gene therapy
EP4700118A3 (en) 2016-07-29 2026-04-22 The Regents of the University of California Adeno-associated virus virions with varint capsid and methods of use thereof
EP3500676A4 (en) * 2016-08-16 2020-07-01 The University of North Carolina at Chapel Hill METHOD AND COMPOSITIONS FOR TARGETED GENE TRANSFER
CN110650673B (en) 2016-08-30 2024-04-09 加利福尼亚大学董事会 Methods for biomedical targeting and delivery and devices and systems for practicing the methods
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
EP3518985A4 (en) 2016-09-29 2020-08-05 University of Florida Research Foundation, Incorporated AAVRH.10 VARIANTS WITH EXIT OPTIONS FOR HOST ANTIBODIES AND CHANGED TISSUE TARGETING PROPERTIES
CA3040483A1 (en) * 2016-10-13 2018-04-19 University Of Massachusetts Aav capsid designs
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
PT3534922T (en) 2016-11-04 2024-06-07 Takeda Pharmaceuticals Co Adeno-associated virus formulations
MA47436A (en) 2017-01-31 2019-12-11 Regenxbio Inc TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY HUMAN ALPHA-L-IDURONIDASE GLYCOSYLATE (IDUA)
CA3114549A1 (en) 2017-02-21 2018-08-30 University Of Florida Research Foundation, Incorporated Modified aav capsid proteins and uses thereof
EP3585898A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
US20200216857A1 (en) 2017-02-22 2020-07-09 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
EP3585807A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
CN119351474A (en) 2017-02-22 2025-01-24 克里斯珀医疗股份公司 Compositions and methods for gene editing
EP3585899A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
AU2018253303B2 (en) 2017-04-14 2024-11-21 Regenxbio Inc. Treatment of mucopolysaccharidosis II with recombinant human iduronate-2 sulfatase (IDS) produced by human neural or glial cells
SG11201909870SA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP2020518259A (en) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Huntington's disease treatment compositions and methods
EP3622073A4 (en) 2017-05-09 2021-01-06 University of Massachusetts AMYOTROPHIC LATERAL SCLEROSIS (ALS) TREATMENT METHODS
AU2018265414B2 (en) 2017-05-10 2022-01-20 Massachusetts Eye And Ear Infirmary Methods and compositions for modifying assembly-activating protein (APP)-dependence of viruses
EP3634450A4 (en) * 2017-05-10 2021-03-31 Massachusetts Eye and Ear Infirmary METHODS AND COMPOSITIONS FOR MODIFYING DEPENDENCE ON A VIRUS ASSEMBLY ACTIVATED PROTEIN (APP)
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
EP3645052A4 (en) 2017-06-30 2021-07-28 Regents of the University of California ADENO-ASSOCIATED VIRUS VIRIONS WITH CAPSID VARIANTS AND METHOD OF USING THEREOF
JP7229989B2 (en) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド Trajectory array guide system
TWI832036B (en) * 2017-08-03 2024-02-11 美商航海家醫療公司 Compositions and methods for delivery of aav
CA3073937A1 (en) * 2017-08-25 2019-02-28 Ovid Therapeutics Inc. Recombinant adeno-associated vectors
KR20200039617A (en) 2017-08-28 2020-04-16 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Adeno-associated virus capsid variants and methods of use thereof
US11739330B2 (en) 2017-09-22 2023-08-29 University Of Massachusetts SOD1 dual expression vectors and uses thereof
MX2020003042A (en) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery.
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
AU2018350992A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
EP3728595A1 (en) 2017-12-21 2020-10-28 CRISPR Therapeutics AG Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
EP3728594A1 (en) 2017-12-21 2020-10-28 CRISPR Therapeutics AG Materials and methods for treatment of usher syndrome type 2a
US12558434B2 (en) 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
KR20250111393A (en) * 2018-03-16 2025-07-22 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 Increasing tissue specific gene delivery by capsid modification
WO2019191418A1 (en) * 2018-03-29 2019-10-03 Asklepios Biopharmaceutical, Inc. Liver tropic recombinant aav6 vectors that evade neutralization
WO2019195444A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
JP7406677B2 (en) 2018-04-03 2023-12-28 ギンコ バイオワークス インコーポレイテッド Viral vectors that evade antibodies
WO2019195423A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
CN108660159B (en) * 2018-04-12 2020-10-30 四川大学 Recombinant bat gland related viral vector and its use
KR102051393B1 (en) 2018-05-04 2019-12-04 (주)지뉴인텍 A recombinant vector for adeno-associated virus based gene delivery and a composition for preventing or treating cancer using the same
WO2019222329A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
US12338267B2 (en) 2018-05-15 2025-06-24 President And Fellows Of Harvard College Viral vectors exhibiting improved gene delivery properties
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
US12163129B2 (en) 2018-06-08 2024-12-10 University Of Massachusetts Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
AU2019299964A1 (en) 2018-07-11 2021-01-21 Takeda Pharmaceutical Company Limited AAV compositions
CA3108324A1 (en) * 2018-07-31 2020-02-06 Cornell University Gene therapy methods to control organ function
US12612644B2 (en) 2018-08-10 2026-04-28 Regenxbio Inc. Scalable method for recombinant AAV production
CN113383010B (en) 2018-09-28 2025-09-09 沃雅戈治疗公司 Ataxin expression constructs with engineered promoters and methods of use thereof
EP3861010A1 (en) 2018-10-02 2021-08-11 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
WO2020077165A1 (en) 2018-10-12 2020-04-16 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
UY38407A (en) 2018-10-15 2020-05-29 Novartis Ag TREM2 STABILIZING ANTIBODIES
AU2019381776A1 (en) * 2018-11-16 2021-07-01 AskBio Inc. Therapeutic adeno-associated virus for treating Pompe disease
GB201900702D0 (en) 2019-01-18 2019-03-06 Univ Bristol Therapy
MX2021008542A (en) 2019-01-18 2021-11-12 Voyager Therapeutics Inc Methods and systems for producing aav particles.
TW202045529A (en) * 2019-02-15 2020-12-16 美商聖加莫治療股份有限公司 Compositions and methods for producing recombinant aav
AR118465A1 (en) 2019-03-21 2021-10-06 Stridebio Inc RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS
CN113994744B (en) * 2019-03-28 2023-05-12 北京小米移动软件有限公司 Paging processing method, equipment, storage medium and system
WO2020205889A1 (en) 2019-04-01 2020-10-08 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
CA3136872A1 (en) * 2019-04-23 2020-10-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) New adeno-associated virus (aav) variants and uses thereof for gene therapy
AU2020263757B2 (en) 2019-04-24 2025-08-28 Takara Bio Inc. AAV mutant having brain-targeting property
US20220194992A1 (en) * 2019-04-26 2022-06-23 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
EP3990030A1 (en) 2019-06-27 2022-05-04 Pfizer Inc. Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
MA56393A (en) 2019-06-28 2022-05-04 Bayer Healthcare Llc MATERIALS AND METHODS OF REGULATING GENE EDITING
WO2021000024A1 (en) * 2019-07-04 2021-01-07 Children's Medical Research Institute Methods and aav vectors for in vivo transduction
EP4006160A4 (en) * 2019-07-12 2023-06-28 Gene Therapy Research Institution Co., Ltd. Adeno-associated virus virion for gene transfer to human liver
KR20220081971A (en) * 2019-07-15 2022-06-16 메이라지티엑스 유케이 Ii 리미티드 Modified AAV Capsid Protein for Treatment of Arthritic Diseases
WO2021030764A1 (en) * 2019-08-14 2021-02-18 University Of Florida Research Foundation, Incorporated Aav capsid variants for gene therapy
WO2021041489A1 (en) * 2019-08-29 2021-03-04 The Board Of Trustees Of The Leland Stanford Junior University Adeno-associated viral vectors for crossing the human blood brain barrier
WO2021046155A1 (en) 2019-09-03 2021-03-11 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
CA3157333A1 (en) * 2019-10-10 2021-04-15 Solid Biosciences Inc. Modified aav capsids and uses thereof
US20220403414A1 (en) * 2019-10-16 2022-12-22 Wuxi Apptec (Shanghai) Co., Ltd. Novel aav variant
KR20220083708A (en) 2019-10-17 2022-06-20 스트라이드바이오 인코포레이티드 AAV delivery cassette
AU2020367532A1 (en) 2019-10-17 2022-05-12 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
EP4055030A4 (en) 2019-11-08 2024-05-22 President And Fellows Of Harvard College VIRAL CAPSID POLYPEPTIDES
US12617821B2 (en) 2019-11-08 2026-05-05 President And Fellows Of Harvard College; Engineered viral capsid polypeptides and uses thereof
JP2023513004A (en) * 2020-01-29 2023-03-30 ジェンザイム・コーポレーション Modified adeno-associated virus capsid proteins for ophthalmic gene therapy and methods of their use
BR112022020753A2 (en) 2020-04-15 2022-12-20 Voyager Therapeutics Inc TAU-BINDING COMPOUNDS
AU2021273447B2 (en) 2020-05-13 2026-03-05 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
GB202010009D0 (en) * 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector
BR112023001456A2 (en) 2020-07-27 2023-04-11 Voyager Therapeutics Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS RELATED TO BETA-GLYCOSYLCERAMIDASE DEFICIENCY
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
CN111825772B (en) * 2020-07-30 2023-10-20 中国科学院精密测量科学与技术创新研究院 Adeno-associated viruses with variant capsid proteins and their applications
TW202214864A (en) 2020-08-06 2022-04-16 應用醫學研究基金會 Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
PH12023550145A1 (en) 2020-08-12 2024-03-18 UCB Biopharma SRL Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences
MX2023002016A (en) 2020-08-19 2023-06-26 Sarepta Therapeutics Inc Adeno-associated virus vectors for treatment of rett syndrome.
IL300738A (en) * 2020-08-28 2023-04-01 Biocad Joint Stock Co Aav5-based vaccine against sars-cov-2
CN113754727B (en) * 2020-09-30 2022-07-12 广州派真生物技术有限公司 Adeno-associated virus mutant and application thereof
AU2021356667A1 (en) * 2020-10-07 2023-06-08 Regenxbio Inc. Adeno-associated viruses for ocular delivery of gene therapy
CN116390935A (en) 2020-10-09 2023-07-04 Ucb生物制药有限责任公司 Nucleic acid construct, viral vector and viral particle
JP7415042B2 (en) 2020-10-09 2024-01-16 テナヤ セラピューティクス， インコーポレイテッド Plakophilin 2 gene therapy methods and compositions
AU2021369480B2 (en) 2020-10-28 2025-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding AAV2.5 vector
WO2022093769A1 (en) * 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
IL302608A (en) 2020-11-03 2023-07-01 Pfizer Methods for producing AAV vectors using ion exchange chromatography
CA3201533A1 (en) 2020-11-11 2022-05-19 European Molecular Biology Laboratory Modified viral particles for gene therapy
WO2022130172A1 (en) 2020-12-15 2022-06-23 Pfizer Inc. Hilic uplc-ms method for separating and analyzing intact adeno-associated virus capsid proteins
CA3205588A1 (en) 2020-12-21 2022-06-30 Pfizer Inc. Methods and systems for improved cell transfection
IL303959A (en) 2020-12-23 2023-08-01 Pfizer Methods for purification of AAV vectors by affinity chromatography
BR112023016075A2 (en) 2021-02-10 2023-11-21 Regenxbio Inc METHOD FOR TREATING HEPATOSPLENOMEGALY, METHOD OF DELIVERY OF A RAAV THAT ENCODS HIDS, METHOD OF TREATING A HUMAN SUBJECT, METHOD OF TREATMENT OF A HUMAN SUBJECT, METHOD OF DETERMINING TREATMENT EFFECTIVENESS, METHOD OF IDENTIFYING A SUBJECT AS HAVING MPS II
GB202101958D0 (en) 2021-02-12 2021-03-31 Ucl Business Ltd Gene therapy for dopamine transporter deficiency syndrome
CN112961219B (en) * 2021-02-24 2022-08-12 中国农业科学院生物技术研究所 Recombinant adeno-associated virus, its mutant and its construction method and application
CN115044614B (en) * 2021-03-09 2023-10-20 上海目镜生物医药科技有限公司 Modified vector of AAV-8 serotype for gene targeting and expression, construction method and application thereof
WO2022208342A1 (en) 2021-04-01 2022-10-06 Pfizer Inc. Pharmaceutical compositions containing adeno-associated viral vector
EP4329820A1 (en) 2021-04-26 2024-03-06 Alexion Pharma International Operations Limited Adeno-associated viral vector capsids with improved tissue tropism
MX2023013138A (en) * 2021-05-07 2024-02-23 Oyster Point Pharma Inc Aav virion encoding neurotrophic factor and uses thereof.
CN117377771A (en) 2021-05-12 2024-01-09 特莱索恩基金会 carrier system
KR20240023638A (en) 2021-06-22 2024-02-22 화이자 인코포레이티드 Production of Adeno-Associated Viral Vectors in Insect Cells
WO2023283962A1 (en) 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
AU2022368907A1 (en) 2021-10-20 2024-05-02 University Of Copenhagen Rejuvenation treatment of age-related white matter loss
JP2024543001A (en) 2021-10-28 2024-11-19 ユーシービー バイオファルマ エスアールエル Nucleic acid constructs, viral vectors and viral particles
IL311861A (en) 2021-11-02 2024-06-01 Voyager Therapeutics Inc Adeno-associated virus capsid variants and their uses
US20230270818A1 (en) 2021-11-02 2023-08-31 University Of Rochester Tcf7l2 mediated remyelination in the brain
CA3238867A1 (en) 2021-11-29 2023-06-01 Shanghai Regenelead Therapies Co., Ltd. Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
WO2023114816A1 (en) 2021-12-14 2023-06-22 Neurogene, Inc. Recombinant optimized galc constructs and methods for treating galc-associated disorders
CN116444626A (en) * 2021-12-28 2023-07-18 成都弘基生物科技有限公司 Modified AAV capsid protein and use thereof
GB202201242D0 (en) 2022-01-31 2022-03-16 Univ Edinburgh Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
CN118660913A (en) 2022-02-21 2024-09-17 上海瑞宏迪医药有限公司 VEGF binding molecules and their medical uses
US12037616B2 (en) 2022-03-01 2024-07-16 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions
CA3255225A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
GB202206336D0 (en) 2022-04-29 2022-06-15 Univ Edinburgh Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
JP2025517628A (en) 2022-05-06 2025-06-10 ノバルティス アーゲー Novel recombinant AAV VP2 fusion polypeptides
WO2024003687A1 (en) 2022-06-28 2024-01-04 Pfizer Inc. Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
WO2024011112A1 (en) * 2022-07-06 2024-01-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024015877A2 (en) * 2022-07-12 2024-01-18 University Of Florida Research Foundation, Incorporated Novel aav3b capsid variants with enhanced hepatocyte tropism
KR20240014846A (en) * 2022-07-26 2024-02-02 숙명여자대학교산학협력단 Pharmaceutical composition for treating alzheheimer's disease comprising aav2-anks1a recombinant virus
WO2024038365A1 (en) 2022-08-16 2024-02-22 Pfizer Inc. Methods for purification of aav vectors by anion exchange chromatography
CN116063404B (en) * 2022-09-27 2025-08-29 广州译码基因科技有限公司 Capsid protein MutD capable of improving AAV packaging capacity and its application
GB202216168D0 (en) 2022-10-31 2022-12-14 UCB Biopharma SRL Route of administration
CN116041443B (en) * 2022-12-30 2023-09-22 广州派真生物技术有限公司 Adeno-associated virus mutants and their applications
CN115925819B (en) * 2022-12-30 2023-10-13 广州派真生物技术有限公司 Adeno-associated virus mutant and application thereof
WO2024148192A1 (en) * 2023-01-05 2024-07-11 Emugen Therapeutics Llc Chimeric aav and uses thereof
AU2023427408A1 (en) 2023-02-02 2025-09-04 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
EP4658294A2 (en) 2023-02-02 2025-12-10 University of Rochester Competitive replacement of glial cells
JP2026509301A (en) 2023-03-14 2026-03-17 ユーシービー バイオファルマ エスアールエル Gene therapy
GB202304767D0 (en) * 2023-03-30 2023-05-17 Ucl Business Ltd Synthetic AAV Capsid
WO2024238853A1 (en) * 2023-05-16 2024-11-21 Regenxbio Inc. Adeno-associated viruses for ocular delivery of gene therapy
US20250027087A1 (en) 2023-07-21 2025-01-23 Crispr Therapeutics Ag Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
TW202508610A (en) 2023-08-23 2025-03-01 大陸商上海瑞宏迪醫藥有限公司 Pharmaceutical composition and use thereof
WO2025049917A1 (en) * 2023-08-31 2025-03-06 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2025090427A1 (en) 2023-10-23 2025-05-01 University Of Rochester Glial-targeted relief of hyperexcitability in neurodegenerative diseases
WO2025108407A2 (en) 2023-11-23 2025-05-30 Neuexcell Therapeutics (Suzhou) Co., Ltd. Gene therapy compositions and methods for treating glioma
WO2025113676A1 (en) 2023-11-29 2025-06-05 Neuexcell Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treating stroke in primates
CN118027157A (en) * 2024-01-16 2024-05-14 广州译码基因科技有限公司 Capsid protein mutant for improving retina penetration capability of AAV virus and application thereof
WO2025186726A1 (en) 2024-03-05 2025-09-12 Crispr Therapeutics Ag Modulating expression of agt (angiotensinogen) gene
WO2025228976A1 (en) 2024-04-29 2025-11-06 UCB Biopharma SRL Gene therapy
GB202407038D0 (en) 2024-05-17 2024-07-03 Axovia Therapeutics Ltd Novel Gene Therapy
WO2025250454A1 (en) 2024-05-28 2025-12-04 University Of Rochester Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
WO2025262203A1 (en) 2024-06-21 2025-12-26 UCB Biopharma SRL Nucleic acid sequences
WO2026017965A1 (en) 2024-07-19 2026-01-22 The University Court Of The University Of Edinburgh Recombinant therapeutic fxn constructs and methods of treating friedreich ataxia and related conditions

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639872A (en) 1993-07-27 1997-06-17 Hybridon, Inc. Human VEGF-specific oligonucleotides
WO1997020925A1 (en) 1995-12-08 1997-06-12 Hybridon, Inc. Modified vegf antisense oligonucleotides for treatment of skin disorders
CA2265460A1 (en) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
AU762220B2 (en) 1998-05-28 2003-06-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The AAV5 vector and uses thereof
EP1127150B1 (en) 1998-11-05 2007-05-16 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US7749492B2 (en) 2001-01-05 2010-07-06 Nationwide Children's Hospital, Inc. AAV vectors and methods
WO2002053703A2 (en) 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
US20030144221A1 (en) 2001-07-17 2003-07-31 Isis Pharmaceuticals Inc. Antisense modulation of BCL2-associated X protein expression
AU2002360355B2 (en) 2001-11-09 2005-07-07 Government Of The United States Of America, Department Of Health And Human Services Production of adeno-associated virus in insect cells
SG10202108118RA (en) 2001-11-13 2021-08-30 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
ES2975413T3 (en) 2001-12-17 2024-07-05 Univ Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors that contain them and their uses
ES2526341T3 (en) 2001-12-17 2015-01-09 The Trustees Of The University Of Pennsylvania Sequences of serotype 9 of adeno-associated virus (AAV), vectors containing them, and uses thereof
ES2467156T3 (en) 2001-12-21 2014-06-12 Medigene Ag A library of modified structural genes or modified capsid particles useful for the identification of viral clones with desired cell tropism
US8802080B2 (en) 2002-05-01 2014-08-12 University Of Florida Research Foundation, Inc. Raav expression systems for genetic modification of specific capsid proteins
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
PL2357189T3 (en) 2003-06-19 2017-08-31 Genzyme Corporation AAV virions with decreased immunoreactivity and uses therefor
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
HUE054805T2 (en) * 2003-09-30 2021-09-28 Univ Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
ES2423060T3 (en) 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. IRNA agents that target VEGF
AU2005316476A1 (en) 2004-12-15 2006-06-22 University Of Florida Research Foundation, Inc. Chimeric vectors
EP3085389A1 (en) * 2005-04-07 2016-10-26 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
US7543116B2 (en) 2006-01-30 2009-06-02 International Business Machines Corporation Data processing system, cache system and method for handling a flush operation in a data processing system having multiple coherency domains
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
CN101495624A (en) * 2006-04-28 2009-07-29 宾夕法尼亚州立大学托管会 Modified AAV vectors having reduced capsid immunogenicity and use thereof
US9198984B2 (en) 2006-04-28 2015-12-01 The Trustees Of The University Of Pennsylvania Scalable production method for AAV
EP2061891B1 (en) 2006-08-24 2012-04-11 Virovek, Inc. Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor
US7872118B2 (en) 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US9611302B2 (en) 2007-04-09 2017-04-04 University Of Florida Research Foundation, Inc. High-transduction-efficiency RAAV vectors, compositions, and methods of use
US9725485B2 (en) * 2012-05-15 2017-08-08 University Of Florida Research Foundation, Inc. AAV vectors with high transduction efficiency and uses thereof for gene therapy
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
US20090215879A1 (en) 2008-02-26 2009-08-27 University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
WO2009137006A2 (en) 2008-04-30 2009-11-12 The University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
US8889641B2 (en) * 2009-02-11 2014-11-18 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
ES2724122T3 (en) 2009-04-30 2019-09-06 Univ Pennsylvania Compositions for directing conductive airway cells comprising adeno-associated virus constructs
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
WO2010141706A1 (en) 2009-06-03 2010-12-09 Cedars-Sinai Medical Center Effective vector platform for gene transfer and gene therapy
EP2457353A1 (en) 2009-07-22 2012-05-30 Aware, Inc. Improved packet detector
EP3567106A1 (en) 2010-04-23 2019-11-13 University of Massachusetts Cns targeting aav vectors and methods of use thereof
CN102071206A (en) * 2010-10-22 2011-05-25 中山大学 Adeno-associated virus capsid protein gene, corresponding protein and application of protein
CN107012171B (en) * 2011-04-22 2021-07-13 加利福尼亚大学董事会 Adeno-associated virus virions with mutated capsids and methods of using the same
EP3147295B2 (en) 2011-08-24 2023-11-22 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
JP6342886B2 (en) * 2012-04-18 2018-06-13 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ Composition and method for highly efficient gene transfer using AAV capsid variants
EP3470523A1 (en) 2012-05-09 2019-04-17 Oregon Health & Science University Adeno associated virus plasmids and vectors
TWI775096B (en) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 Treatment of amd using aav sflt-1
US10294281B2 (en) 2012-05-15 2019-05-21 University Of Florida Research Foundation, Incorporated High-transduction-efficiency rAAV vectors, compositions, and methods of use
US10006049B2 (en) 2013-05-16 2018-06-26 University Of Florida Research Foundation, Incorporated Hairpin mRNA elements and methods for the regulation of protein translation
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
ES2768763T3 (en) 2014-03-04 2020-06-23 Univ Florida Enhanced rAAV vectors and methods for transduction of photoreceptors and EPR cells
US10648000B2 (en) 2015-02-16 2020-05-12 University Of Florida Research Foundation, Incorporated rAAV vector compositions, methods for targeting vascular endothelial cells and use in treatment of type I diabetes
IL314171A (en) 2015-09-28 2024-09-01 Univ Florida Methods and compositions for stealth virus antibody vectors
WO2017066764A2 (en) 2015-10-16 2017-04-20 William Marsh Rice University Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3485005A1 (en) 2016-07-12 2019-05-22 The University Of Manchester Gene therapy

Also Published As

Publication number Publication date
GB201403684D0 (en) 2014-04-16
SI3108000T1 (en) 2020-02-28
US20180135076A1 (en) 2018-05-17
IL247332A0 (en) 2016-09-29
CA3126061C (en) 2023-08-29
AU2015216847B2 (en) 2021-05-20
US20240124894A1 (en) 2024-04-18
AU2021202538A1 (en) 2021-05-27
IL279154A (en) 2021-01-31
US20210238631A1 (en) 2021-08-05
JP2021137016A (en) 2021-09-16
JP2020022476A (en) 2020-02-13
IL279154B (en) 2022-06-01
WO2015121501A1 (en) 2015-08-20
CA3126061A1 (en) 2015-08-20
JP2023126885A (en) 2023-09-12
AU2021202538B2 (en) 2023-08-03
BR112016018598A2 (en) 2017-10-17
AU2015216847A1 (en) 2016-08-11
US20220106612A1 (en) 2022-04-07
EP3597760A3 (en) 2020-03-11
CN106062200B (en) 2020-06-23
RU2016133623A3 (en) 2018-11-16
JP7309780B2 (en) 2023-07-18
JP2017506521A (en) 2017-03-09
JP6602788B2 (en) 2019-11-06
HUE045801T2 (en) 2020-01-28
KR20160130996A (en) 2016-11-15
CA2939612C (en) 2021-10-12
CA2939612A1 (en) 2015-08-20
PL3108000T3 (en) 2020-05-18
PT3108000T (en) 2019-10-25
CN106062200A (en) 2016-10-26
AU2023258448B2 (en) 2026-03-26
EP3108000B1 (en) 2019-08-28
US11802293B2 (en) 2023-10-31
RU2021102290A (en) 2021-03-01
EP3597760A2 (en) 2020-01-22
AU2023258448A1 (en) 2023-12-07
SG11201606365TA (en) 2016-09-29
RU2743382C2 (en) 2021-02-17
DK3108000T3 (en) 2019-10-28
JP7612767B2 (en) 2025-01-14
MX372992B (en) 2020-05-12
JP6942166B2 (en) 2021-09-29
KR102082032B1 (en) 2020-02-26
RU2016133623A (en) 2018-03-22
EP3108000A1 (en) 2016-12-28
ES2749235T3 (en) 2020-03-19
MX2016010649A (en) 2017-05-04

Similar Documents

Publication Publication Date Title
IL279154B (en) Adeno-associated virus vector
GB201401707D0 (en) Adeno-associated viral vectors
PT3145949T (en) Lentiviral vectors
BR112016015519A2 (en)
BR112016003131A2 (en)
GB201406608D0 (en) Virus
BR112015027867A2 (en)
BR112016012568A2 (en)
BR112016015798A2 (en)
BR112016021958A2 (en)
BR112016014482A2 (en)
BR112016015538A2 (en)
BR112016015054A2 (en)
BR112016015896A2 (en)
GB201419572D0 (en) Virus
BR112016015729A2 (en)
BR112016015986A2 (en)
GB201419965D0 (en) Fan
BR112016015533A2 (en)
BR112016015346A2 (en)
TWI563175B (en) Fan
BR102014025482A8 (en)
TWI563176B (en) Fan
GB201406470D0 (en) Virus
GB201403582D0 (en) Virus